News | February 14, 2025
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The inspection was carried out from January 28 to February 1, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
The trademark rights for these brands will be transferred to Lupin by March next year.
Reaffirms Lupin’s commitment to sustainable resource management
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The facility is a part of Lupin Manufacturing Solutions
Subscribe To Our Newsletter & Stay Updated
